Financial Performance

Bilcare Limited reported mixed financial results for FY 2025-26. On a consolidated basis, the company achieved a net profit of ₹172.84 lacs, marking a significant turnaround from the net loss of ₹78.36 lacs in FY25. However, standalone operations showed revenue decline to ₹6.85 crore (from ₹15.12 crore previous year) with net profit of ₹0.99 crore. Consolidated operations reported a total net loss of ₹17.28 crore for the year.

Corporate Governance and Board Changes

The Board approved important modifications to director appointments, reducing the tenure of Executive Directors Mohan Bhandari and Kavita Bhansali from 5 years to 3 years, effective August 2026. These changes are subject to shareholder approval at the upcoming 39th Annual General Meeting scheduled for September 26, 2026, to be held via video conference.

Key AGM Agenda Items

The AGM will consider several critical matters including:

  • Adoption of audited standalone and consolidated financial statements for FY26
  • Re-appointment of Dr. Kavita Bhansali as Executive Director with maximum annual remuneration of ₹99.00 lacs
  • Appointment of Mr. Mohan Bhandari as Executive Director with maximum annual remuneration of ₹125.40 lacs
  • Approval of material related party transactions with subsidiary Caprihans India Limited, including inter-corporate deposits up to ₹70 crore and corporate guarantees up to ₹30 crore

Subsidiary and Corporate Developments

The company completed the liquidation of UK subsidiary Bilcare GCS Limited and resolved its public fixed deposit obligations by transferring ₹2.93 crore to IEPF following an NCLT order. In subsidiary Caprihans India Limited, the company converted warrants into equity shares, increasing its holding from 55.99% to 63.47%.

Financial Restatement and Compliance

The financial statements include restated comparative figures for FY25 due to correction of prior period errors relating to lease accounting and PPE measurement, resulting in an adjustment of ₹59,055.32 lacs to the opening balance sheet. The company continues to face SFIO investigation, with a writ petition challenging the investigation pending in court.

Contingent Liabilities and Risk Management

Significant contingent liabilities include penal interest for CSIR loan (₹1,772.14 lacs pending legal case) and corporate guarantees given (₹66,696.00 lacs). The company is exposed to credit risk, liquidity risk, and market risk, primarily foreign currency risk.

Operational Highlights

The company operates primarily in the Pharma Packaging Research Solutions segment, with geographical revenue split of ₹47,447.62 lacs within India and ₹25,906.05 lacs outside India. During the year, the company filed two new international patent applications and implemented energy conservation measures saving ₹99,128.16.